November 24, 2021
Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference
November 19, 2021
Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors
November 11, 2021
Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders
We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products.
ALKS 1140 - Neurology
ALKS 2680 - Narcolepsy
Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer
Nemvaleukin alfa - Mucosal Melanoma